Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
Alumis (Nasdaq: ALMS) has announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference. President and CEO Martin Babler will engage in a fireside chat on Tuesday, November 12, 2024, at 2:00 pm ET in Boston, MA. The clinical-stage biopharmaceutical company, which focuses on developing oral therapies for immune-mediated diseases using precision approaches, will provide a live webcast of the event on their website's Investors section. The webcast recording will remain accessible for 90 days after the event.
Alumis (Nasdaq: ALMS) ha annunciato la sua partecipazione alla Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim. Il presidente e CEO Martin Babler parteciperà a una conversazione informale martedì 12 novembre 2024, alle 14:00 ET a Boston, MA. L'azienda biofarmaceutica in fase clinica, che si concentra sullo sviluppo di terapie orali per malattie mediate dal sistema immunitario utilizzando approcci di precisione, offrirà una diretta dell'evento nella sezione Investitori del loro sito web. La registrazione del webcast rimarrà accessibile per 90 giorni dopo l'evento.
Alumis (Nasdaq: ALMS) ha anunciado su participación en la Conferencia Inaugural sobre Innovación en Salud de Guggenheim. El presidente y director ejecutivo Martin Babler participará en una charla informal el martes 12 de noviembre de 2024, a las 2:00 pm ET en Boston, MA. La compañía biofarmacéutica en fase clínica, que se centra en desarrollar terapias orales para enfermedades mediadas por el sistema inmunitario utilizando enfoques de precisión, ofrecerá una transmisión en vivo del evento en la sección de Inversores de su sitio web. La grabación de la transmisión estará disponible durante 90 días después del evento.
Alumis (Nasdaq: ALMS)는 구겐하임 최초의 헬스케어 혁신 컨퍼런스에 참가한다고 발표했습니다. 회장 겸 CEO인 마틴 바블러는 2024년 11월 12일 화요일 오후 2시(동부표준시) 보스턴, MA에서 난방담화에 참여합니다. 면역 매개 질환을 위한 경구 요법을 정밀 접근법을 사용하여 개발하는 데 초점을 맞춘 임상 단계의 생물 제약 회사는 웹사이트의 투자자 섹션에서 이벤트의 생중계를 제공합니다. 웹캐스트 녹화는 이벤트 후 90일 동안 접근 가능합니다.
Alumis (Nasdaq: ALMS) a annoncé sa participation à la Conférence Inaugurale sur l'Innovation en Santé de Guggenheim. Le président et PDG Martin Babler participera à une discussion informelle le mardi 12 novembre 2024, à 14h00 ET à Boston, MA. L'entreprise biopharmaceutique en phase clinique, qui se concentre sur le développement de thérapies orales pour les maladies médiées par le système immunitaire à l'aide d'approches de précision, proposera une diffusion en direct de l'événement dans la section Investisseurs de son site web. L'enregistrement de la diffusion restera accessible pendant 90 jours après l'événement.
Alumis (Nasdaq: ALMS) hat seine Teilnahme an der Ersten Gesundheitsinnovationskonferenz von Guggenheim angekündigt. Präsident und CEO Martin Babler wird am Dienstag, den 12. November 2024, um 14:00 Uhr ET in Boston, MA, an einem informellen Gespräch teilnehmen. Das biopharmazeutische Unternehmen in der klinischen Phase, das sich auf die Entwicklung von oralen Therapien für immunmediierte Erkrankungen mit präzisen Ansätzen konzentriert, wird eine Live-Übertragung der Veranstaltung im Bereich Investoren auf ihrer Website anbieten. Die Aufzeichnung der Übertragung bleibt 90 Tage nach der Veranstaltung abrufbar.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 2:00 pm ET in Boston, MA.
A live webcast will be available on the Alumis website in the "Investors" section under the “Events” page. A replay of the conference webcast will be archived on the company's website for 90 days.
About Alumis
Alumis is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. Leveraging its proprietary precision data analytics platform, Alumis is building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases as monotherapy or combination therapies. Alumis’ most advanced product candidate, ESK-001, is an oral, highly selective, small molecule, allosteric inhibitor of tyrosine kinase 2 (TYK2) that is currently being evaluated for the treatment of patients with moderate-to-severe plaque psoriasis and systemic lupus erythematosus. Alumis is also developing A-005, a CNS-penetrant, allosteric TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases. Beyond TYK2, Alumis’ proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify its precision approach. Incubated by Foresite Labs and led by a team of industry veterans experienced in small-molecule compound drug development for immune-mediated diseases, Alumis is pioneering a precision approach to drug development to potentially produce the next generation of treatment to address immune dysfunction. For more information, visit www.alumis.com.
Forward Looking Statements
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding Alumis’ participation at upcoming conferences. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
FAQ
When is Alumis (ALMS) presenting at Guggenheim's Healthcare Innovation Conference 2024?
How long will Alumis (ALMS) conference webcast be available for replay?
What type of treatments does Alumis (ALMS) develop?
Where can I watch Alumis's (ALMS) Guggenheim conference presentation?
